April 2015

MabVax Therapeutics Announces Closing of FinancingPR Newswire (press release)Each Unit consists of one share of common stock and a 30-month warrant to purchase one-half of one share of common stock (the “Warrant”). The Warrants are exercisable at $1.50 per each whole share of common stock. Laidlaw & Company (UK) Ltd. acted … and more …read […]

Larry G. Swets, Jr. – Press ReleaseMarketWatchAssuming the exercise of the Stock Options in full (and assuming no other outstanding stock options of the Company were exercised), Mr. Swets owned, directly or indirectly, 2,259,144 common shares of the Company on March 28, 2014, representing … the … and more …read more

MabVax Therapeutics Announces Closing of FinancingMarketWatchEach Unit consists of one share of common stock and a 30-month warrant to purchase one-half of one share of common stock (the “Warrant”). The Warrants are exercisable at $1.50 per each whole share of common stock. Laidlaw & Company (UK) Ltd. acted … and more …read more

Opexa Therapeutics Reminds Shareholders That Rights Offering Expires on …Business Wire (press release)The non-transferable subscription rights entitle holders of Opexa common stock and holders of outstanding Series L warrants as of March 13, 2015 (the record date) to purchase units, composed of one share of common stock and a warrant to purchase … and more

Cortex Pharmaceuticals, Inc. Files December 31, 2014 Annual Report on Form …GlobeNewswire (press release)The Company incurred a net loss attributable to common stockholders of $12,768,307 for the year ended December 31, 2014 (including adjustments related to the Series G 1.5% Convertible Preferred Stock of $10,060,772), reflecting a net loss per share of … and more